There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Aerie Pharma (AERI), Incyte Corp (INCY) and Celyad (CYAD) with bullish sentiments.
Aerie Pharma (AERI)
In a report released yesterday, Ken Cacciatore from Cowen & Co. maintained a Buy rating on Aerie Pharma, with a price target of $105. The company’s shares closed yesterday at $33.29, close to its 52-week low of $31.01.
According to TipRanks.com, Cacciatore ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -3.6% and a 41.0% success rate. Cacciatore covers the Healthcare sector, focusing on stocks such as Alder Biopharmaceuticals, Amag Pharmaceuticals, and Jazz Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Aerie Pharma with a $75.43 average price target, a 126.6% upside from current levels. In a report issued on June 11, Canaccord Genuity also maintained a Buy rating on the stock with a $56 price target.
See today’s analyst top recommended stocks >>
Incyte Corp (INCY)
J.P. Morgan analyst Cory Kasimov maintained a Buy rating on Incyte Corp yesterday. The company’s shares closed yesterday at $81.84.
According to TipRanks.com, Kasimov is a 3-star analyst with an average return of 0.5% and a 41.6% success rate. Kasimov covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Inc., BioMarin Pharmaceutical Inc., and ACADIA Pharmaceuticals Inc.
Incyte Corp has an analyst consensus of Moderate Buy, with a price target consensus of $83.40, a 1.9% upside from current levels. In a report released yesterday, Piper Jaffray also maintained a Buy rating on the stock.
Celyad (CYAD)
William Blair analyst Raju Prasad maintained a Buy rating on Celyad yesterday. The company’s shares closed yesterday at $13.50, close to its 52-week low of $13.
Prasad said:
“We anticipate updates in mCRC from the autologous and allogeneic NKG2D products at the European Society for Medical Oncology (ESMO)’s World Congress on Gastrointestinal Cancer (WCGIC) on July 3-6 as well as an update from the r/r AML trials by year-end along with a go-forward Phase II treatment paradigm.”
According to TipRanks.com, Prasad is a 5-star analyst with an average return of 14.4% and a 57.1% success rate. Prasad covers the Healthcare sector, focusing on stocks such as Rocket Pharmaceuticals Inc, Global Blood Therapeutics, and Allogene Therapeutics Inc.
Currently, the analyst consensus on Celyad is a Strong Buy with an average price target of $51, implying a 277.8% upside from current levels. In a report released yesterday, H.C. Wainwright also maintained a Buy rating on the stock with a $52 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
